Oncotarget podcast

KRAS G12C Mutation Identified as a Rare Potential Target in Genitourinary Cancers

17/11/2026
0:00
12:57
Reculer de 15 secondes
Avancer de 15 secondes
Precision cancer treatment increasingly depends on finding genetic changes that can be matched with specific drugs. One such alteration, called KRAS G12C, has already become an important treatment target in several cancers. But its role in cancers of the urinary and reproductive systems has been less clear. A research paper recently published in Volume 17 of Oncotarget, titled “Incidence of KRAS G12C mutations in genitourinary malignancies; emerging target in precision medicine,” examined how often KRAS G12C occurs in three major genitourinary cancers and what other molecular features accompany it. The study was led by first author Kelly Crane and corresponding author K. R. Seetharam Bhat, both affiliated with the Department of Urology at SUNY Upstate Medical University. Bhat is also affiliated with Upstate Urology at MVHS. The researchers analyzed more than 13,600 tumor specimens and found that KRAS G12C was rare overall. It appeared most often in urothelial bladder cancer, while only one prostate cancer carried the mutation and none of the renal clear cell cancers did. The rarity of the mutation does not make it irrelevant. Because drugs already exist that specifically target KRAS G12C in other malignancies, identifying the same alteration in a small number of genitourinary tumors could eventually open treatment or clinical-trial options that would otherwise not be considered. Full blog post - https://www.oncotarget.org/2026/11/17/kras-g12c-mutation-identified-as-a-rare-potential-target-in-genitourinary-cancers/ DOI - https://doi.org/10.18632/oncotarget.28912 Correspondence to - K. R. Seetharam Bhat - [email protected] Abstract video - https://www.youtube.com/watch?v=me9HXtnDmp4 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28912 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, KRAS mutation, genitourinary malignancy, precision medicine, emerging target To learn more about the journal, please visit https://www.oncotarget.com and connect with us on social media: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh [email protected]

D'autres épisodes de "Oncotarget"